CureVac

Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Saturday, May 21, 2022
Other Health, Research, General Health, Pharmaceutical, Oncology, Medical Devices, Hospitals, Clinical Trials, Science, Biotechnology, FDA, Health, Employment, Severe acute respiratory syndrome coronavirus 2, RNA transfection, DNA, Company, Private Securities Litigation Reform Act, Cystic Fibrosis Foundation, NASH, Duke–NUS Medical School, Nasdaq, Messenger RNA, Cystic fibrosis, ARCT, Vaccine, OTC, Gene editing, Financial compensation, Liver, CureVac, COVID-19, Fatty liver disease, Patent, Johnson & Johnson, Takeda Pharmaceutical Company, Intention, Janssen Pharmaceuticals, Infection, Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., RNA, III, Safety, Glycogen storage disease type III, MicroRNA, Hepatitis B virus, LinkedIn, Twitter, Therapy, SEC, Director, Risk, Annual report, Arcturus

The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individuals employment compensation and were granted as an inducement material to his or her acceptance of employment with the Company.

Key Points: 
  • The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individuals employment compensation and were granted as an inducement material to his or her acceptance of employment with the Company.
  • The options have an exercise price equal to $16.84 per share, the closing price of the Companys common stock as reported by Nasdaq on May 16, 2022.
  • Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.
  • Arcturus technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China and other countries).

Arcturus Therapeutics Announces First Quarter 2022 Financial Update and Pipeline Progress

Retrieved on: 
Monday, May 9, 2022
Research, Infectious Diseases, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, COVID-19, Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., Cystic fibrosis, Private Securities Litigation Reform Act, Messenger RNA, Nasdaq, Twitter, CureVac, RNA, Safety, Janssen Pharmaceuticals, HBV, Johnson & Johnson, Glycogen storage disease type III, COVID, Trial of the century, Duke–NUS Medical School, OTC, Gene editing, III, Risk, Annual report, GSD, Therapy, Patent, DNA, Cystic Fibrosis Foundation, Severe acute respiratory syndrome coronavirus 2, Vaccine, LinkedIn, Intention, NASH, Fatty liver disease, Takeda Pharmaceutical Company, SEC, RNA transfection, Hepatitis B virus, ARCT, MicroRNA, Arcturus

Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, self-amplifying mRNA, small interfering RNA, circular RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.

Key Points: 
  • Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, self-amplifying mRNA, small interfering RNA, circular RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.
  • Arcturus technologies are covered by its extensive patent portfolio (with patents and patent applications issued in the U.S., Europe, Japan, China and other countries).
  • The Arcturus logo and other trademarks of Arcturus appearing in this announcement, including LUNAR and STARR, are the property of Arcturus.
  • All other trademarks, services marks, and trade names in this announcement are the property of their respective owners.

Arcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster Trial

Retrieved on: 
Thursday, May 5, 2022
Infectious Diseases, Pharmaceutical, Health, Clinical Trials, COVID-19, Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., Cystic fibrosis, Private Securities Litigation Reform Act, Omicron, Nasdaq, Messenger RNA, Twitter, CureVac, RNA, Company, MicroRNA, Time, Janssen Pharmaceuticals, HBV, Johnson & Johnson, Glycogen storage disease type III, COVID, Duke–NUS Medical School, Clinical trial, OTC, Gene editing, MNT, III, Risk, Annual report, GSD, Therapy, Patent, CRO, DNA, D614G, Multimedia, Cystic Fibrosis Foundation, Severe acute respiratory syndrome coronavirus 2, Beta, Vaccine, Arcturus Therapeutics, LinkedIn, Intention, NASH, Infection, Fatty liver disease, Liver, Takeda Pharmaceutical Company, SEC, Vaccination, RNA transfection, CEO, Hepatitis B virus, ARCT, Interval (mathematics), Arcturus, Infectious Diseases, Pharmaceutical, Health, Clinical Trials

These results provide additional validation of Arcturus next generation STARR mRNA technology for vaccines.

Key Points: 
  • These results provide additional validation of Arcturus next generation STARR mRNA technology for vaccines.
  • Samples from the trial will be further analyzed for neutralizing antibody activity against different strains of SARS-CoV-2, including the Omicron lineage.
  • The Company has initiated start-up activities with an international CRO toward a pivotal Phase 3 booster trial intended to support global registration.
  • The Arcturus logo and other trademarks of Arcturus appearing in this announcement, including LUNAR and STARR, are the property of Arcturus.

Arcturus Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on May 9, 2022

Retrieved on: 
Wednesday, April 27, 2022
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Patent, DNA, Duke–NUS Medical School, ARCT, MicroRNA, Hepatitis B virus, Cystic Fibrosis Foundation, COVID-19, Twitter, Diversified Specialty Institute Holdings, Inc., HBV, Cystic fibrosis, NASH, Messenger RNA, RNA, Fatty liver disease, Therapy, OTC, Janssen Pharmaceuticals, Gene editing, LinkedIn, III, Vaccine, Nasdaq, Johnson & Johnson, CureVac, Takeda Pharmaceutical Company, RNA transfection, GSD, Severe acute respiratory syndrome coronavirus 2, Glycogen storage disease type III, Baking

Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.

Key Points: 
  • Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.
  • Arcturus technologies are covered by its extensive patent portfolio (with patents and patent applications issued in the U.S., Europe, Japan, China and other countries).
  • In addition, please connect with us on Twitter and LinkedIn .
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20220427005396/en/

Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Saturday, April 23, 2022
Other Health, Health, Science, Other Science, Research, Patent, DNA, Duke–NUS Medical School, ARCT, MicroRNA, Hepatitis B virus, Cystic fibrosis, Cystic Fibrosis Foundation, COVID-19, Twitter, Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., Intention, Annual report, NASH, Messenger RNA, Private Securities Litigation Reform Act, RNA, Fatty liver disease, Therapy, Risk, OTC, Janssen Pharmaceuticals, Infection, Gene editing, LinkedIn, III, Employment, Vaccine, Nasdaq, Company, Johnson & Johnson, CureVac, Takeda Pharmaceutical Company, SEC, Director, Safety, Financial compensation, RNA transfection, Liver, Severe acute respiratory syndrome coronavirus 2, Glycogen storage disease type III, Arcturus

The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individuals employment compensation and were granted as an inducement material to his or her acceptance of employment with the Company.

Key Points: 
  • The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individuals employment compensation and were granted as an inducement material to his or her acceptance of employment with the Company.
  • The options have an exercise price equal to $25.24 per share, the closing price of the Companys common stock as reported by Nasdaq on April 18, 2022.
  • Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.
  • Arcturus technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China and other countries).

DGAP-News: CureVac to Report Fourth Quarter and Full-Year 2021 Financial Results and Business Updates on April 28, 2022

Retrieved on: 
Friday, April 22, 2022
EDGAR, U.S. Securities and Exchange Commission, COVID-19, Legislation, Private Securities Litigation Reform Act, News, Terminology, Patient safety, Growth, Gesellschaft mit beschränkter Haftung, SEC, Forward-looking statement, Industry, DGAP, Instability, CureVac, Security (finance)

Examples include discussion of the potential efficacy of the company's vaccine and treatment candidates and the company's strategies, financing plans, growth opportunities and market growth.

Key Points: 
  • Examples include discussion of the potential efficacy of the company's vaccine and treatment candidates and the company's strategies, financing plans, growth opportunities and market growth.
  • Forward-looking statements are based on management's current beliefs and assumptions and on information currently available to the company.
  • However, these forward-looking statements are not a guarantee of the company's performance, and you should not place undue reliance on such statements.
  • Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements.

DGAP-News: CureVac and GSK's Bivalent Second-Generation mRNA Vaccine Candidate Shown to be Highly Effective Against SARS-CoV-2 Variants in Preclinical Study

Retrieved on: 
Thursday, April 21, 2022
Protein, Manuscript, Friedrich Loeffler Institute, COVID-19, Degenerative disease, RNA, GSK, CVAC, Infection, Technology, Virulence, Vaccine, Nasdaq, ACE2, Flow cytometry, Animal, Viral load, Wistar, RNA transfection, Omicron, BioRxiv, CureVac, Delta

The preclinical study, conducted in collaboration with the Friedrich-Loeffler-Institut, Germany, assessed the bivalent candidate in comparison to the corresponding monovalent candidates targeting either variant in a mouse model.

Key Points: 
  • The preclinical study, conducted in collaboration with the Friedrich-Loeffler-Institut, Germany, assessed the bivalent candidate in comparison to the corresponding monovalent candidates targeting either variant in a mouse model.
  • During exposure of the vaccinated animals to either the Beta or the Delta variant, the bivalent mRNA vaccine significantly reduced the viral load in the animals.
  • Notably, the bivalent Beta /Delta vaccine candidate induced two-fold higher virus neutralizing antibody titers against the Omicron variant than against the Delta variant in a rat model.
  • This collaboration was later extended to the development of second-generation COVID-19 vaccine candidates, and modified mRNA vaccine technologies.

DGAP-News: CureVac and GSK Enter into Pandemic Preparedness Contract with German Government

Retrieved on: 
Tuesday, April 12, 2022
CureVac, Pandemic, GSK, Global Health, Degenerative disease, Federation, RNA, Technology, Infection, RNA transfection, Nasdaq, COVID-19, CVAC, Protein, Vaccine, Pharmaceutical industry, Vaccine

By reserving this manufacturing capacity, the tender seeks to mitigate risks associated with potential supply bottlenecks in a pandemic situation.

Key Points: 
  • By reserving this manufacturing capacity, the tender seeks to mitigate risks associated with potential supply bottlenecks in a pandemic situation.
  • Under the contract, the federal government will pay CureVac and GSK an annual standby fee after successful completion of the setup period, which requires the companies to maintain manufacturing capacity at constant readiness.
  • By ensuring the availability of manufacturing capacities in Germany, the arrangement will significantly contribute to strengthening pandemic preparedness.
  • "We welcome this announcement of the German federal government, which aims to strengthen the country's preparedness against future pandemics," said Roger Connor, President of Vaccines and Global Health, GSK.

DGAP-News: CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV

Retrieved on: 
Friday, April 1, 2022
CureVac, GSK, Degenerative disease, Trial of the century, Clinical trial, Vaccine, Italian LNP Cup, Program, RNA, CureVac COVID-19 vaccine, SM-102, Safety, Technology, RNA transfection, Nasdaq, COVID-19, CVAC, Animal, Protein, Infection, Pharmaceutical industry, Nature

CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV

Key Points: 
  • CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV
    The issuer is solely responsible for the content of this announcement.
  • CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV
    - Phase 1 dose-escalation study started at clinical sites in the U.S.
    TBINGEN, Germany/ BOSTON, USA - March 30, 2022 - CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that the first participant was dosed in a Phase 1 study of COVID-19 second-generation mRNA vaccine candidate, CV2CoV, developed in collaboration with GSK.
  • CV2CoV is CureVac's first COVID-19 vaccine candidate based on the advanced second-generation mRNA backbone from the broad second-generation program, currently developed in collaboration with GSK.
  • This collaboration was later extended to the development of second-generation COVID-19 vaccine candidates and modified mRNA vaccine technologies.

Arcturus Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit

Retrieved on: 
Friday, March 25, 2022
Biotechnology, Other Health, Health, General Health, Pharmaceutical, Research, Infectious Diseases, Hospitals, Genetics, Science, Clinical Trials, ARCT, CureVac, Hepatitis B virus, Therapy, Janssen Pharmaceuticals, LinkedIn, Fatty liver disease, Duke–NUS Medical School, DNA, Patent, III, Cystic fibrosis, Vaccine, Liver, Messenger RNA, Conference, CEO, RNA, Severe acute respiratory syndrome coronavirus 2, MicroRNA, NASH, Infection, Gene editing, Twitter, RNA transfection, Glycogen storage disease type III, Nasdaq, COVID-19, Diversified Specialty Institute Holdings, Inc., Cystic Fibrosis Foundation, Takeda Pharmaceutical Company, OTC, Arcturus Therapeutics, Johnson & Johnson, Biotechnology, Other Health, Health, General Health, Pharmaceutical, Research, Infectious Diseases, Hospitals, Genetics, Science, Clinical Trials

Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that Joseph Payne, President and CEO of Arcturus Therapeutics, will participate in a panel discussion titled RNA Therapeutics in Rare Diseases at the Cantor Fitzgerald Virtual rare Disease Summit on Barclays Global Healthcare Conference on Tuesday, March 29, 2022 at 2:45 p.m.

Key Points: 
  • Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that Joseph Payne, President and CEO of Arcturus Therapeutics, will participate in a panel discussion titled RNA Therapeutics in Rare Diseases at the Cantor Fitzgerald Virtual rare Disease Summit on Barclays Global Healthcare Conference on Tuesday, March 29, 2022 at 2:45 p.m.
  • Those interested in participating in the Cantor Fitzgerald Virtual Rare Disease Summit are encouraged to contact their Cantor Fitzgerald representative.
  • Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.
  • Arcturus technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China and other countries).